Lineage Cell Therapeutics, Inc. LCTX
1.03
0.08
8.42%
as of 25 Sep
- Market cap
- $239.7M
- P/E
- 0.0×
Follow LCTX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(158.10%) | (105.57%) | (98.51%) | (60.35%) | |
| (72.66%) | (56.27%) | (58.03%) | (32.75%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (186.79%) | |
Return on Tangible Assets |
(193.11%) | (126.17%) | (127.11%) | (67.96%) | |
Average Days of Receivables |
4.29 | 22.34 | 19.91 | 22.04 | |
Free Cash Flow per Share |
(0.09) | (0.08) | (0.09) | (0.10) | |
Free Cash Flow |
(20.87) | (19.44) | (22.59) | (24.39) | |
Capital Expenditures |
(0.49) | (0.52) | (0.48) | (0.57) | |
Piotroski F-Score |
5.00 | 5.00 | 5.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
(33.25%) | (19.08%) | (20.84%) | (21.53%) | |
Accounts Receivable Turnover |
40.66 | 19.04 | 29.01 | 25.02 | |
Accounts Payable Turnover |
0.05 | 0.02 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
7,097.22 | 17,952.50 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
119.40% | 121.80% | 127.54% | 156.82% | |
Selling, General and Administrative Expense of Revenue |
166.50% | 126.82% | 126.44% | 147.86% | |
Share Based Compensation of Revenue |
45.94% | 32.65% | 31.85% | 38.75% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.30 | 0.30 | 0.34 | 0.74 | |
Depreciation/Fixed assets |
7.16 | 6.03 | 6.21 | 0.33 | |
Capex/Depreciation |
(0.03) | (0.03) | (0.03) | (0.70) | |
Revenue per Share |
0.05 | 0.06 | 0.06 | 0.05 | |
Operating CF per Share |
(0.09) | (0.08) | (0.09) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.04 | 0.03 | 0.04 | |
Net Profit Margin |
(625.53%) | (436.47%) | (434.44%) | (246.58%) |
Columns are period end dates